{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28"}]}],"title":"Patients able to continue treatment during induction period without dose interruptions or delays"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Patients who missed one or more doses during induction period"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Patients requiring dose reduction(s) during induction period"}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"description":"The percentage of participants who are able to continue on treatment without dose interruptions or delays was defined as not having to delay or interrupt treatment due to toxicity or intolerability for more than two weeks during the 12-week induction period.","groups":[{"description":"Administration: Decitabine is reconstituted with 5 ml sterile water to facilitate subcutaneous administration. Decitabine is given by subcutaneous injection. Venetoclax is taken as a tablet prepared by patients pharmacy. Venetoclax is given at a dose of 400 mg po once per week concurrently with the Decitabine dose (+/- 1 day allowed ).\n\nVenetoclax: Venetoclax 400 mg po on days 1, 8, 15 and 28 of each cycle (28day cycle)\n\nDecitabine: Decitabine 0.2 mg/kg SQ (subcutaneous) on days 2, 9, 16, 23 (for aggressive disease will add decitabine on days 3, 10, 17, 24)","id":"OG000","title":"Decitabine/Venetoclax (Single Arm)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 12 weeks","title":"Percentage of Participants Who Are Able to Continue on Treatment Without Dose Interruptions or Delays","type":"PRIMARY","unitOfMeasure":"Participants"}